Under Cornerstone’s Ownership, Zyflo Asthma Med Repositioned For Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
After completing a reverse merger with Critical Therapeutics last year, Cornerstone has retooled the marketing message for the asthma medication and ramped up commercial support.
You may also be interested in...
Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
Critical Therapeutics, Cornerstone BioPharma To Merge
Critical had been in line for delisting from NASDAQ; new firm, Cornerstone Therapeutics, will apply to relist.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.